Semaglutide vs Retatrutide: GLP-1 vs Triple Agonist for Weight Loss

GLP-1 receptor agonists like semaglutide have reshaped obesity medicine over the past five years. Now a new class of molecule is entering the picture: triple agonists that hit three metabolic receptors simultaneously. Retatrutide is the lead candidate in this category, and early data suggests it may produce weight loss that eclipses anything seen with current approved medications.

This guide compares semaglutide and retatrutide head-to-head across mechanism, efficacy, side effects, and practical availability so you can understand where the science currently stands.

How Semaglutide Works

Semaglutide is a GLP-1 receptor agonist. It mimics glucagon-like peptide-1, a gut hormone released after eating. By binding the GLP-1 receptor, semaglutide:

• Slows gastric emptying, prolonging satiety
• Increases insulin secretion in a glucose-dependent manner
• Suppresses glucagon release, reducing hepatic glucose output
• Acts on hypothalamic appetite centers to reduce caloric drive

At the 2.4 mg weekly dose used in the STEP trials (Wegovy), semaglutide produced an average of 14.9% body weight reduction over 68 weeks in people with obesity but without diabetes. In participants who also had type 2 diabetes, average reduction was closer to 6–9% due to the competing metabolic environment. These numbers made semaglutide one of the most effective anti-obesity medications ever approved by the FDA.

How Retatrutide Works

Retatrutide is a triple agonist: it activates GLP-1, GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors simultaneously. That third receptor—glucagon—is the critical differentiator.

While glucagon raises blood sugar in isolation, combining glucagon receptor agonism with GLP-1 action appears to amplify energy expenditure through the liver and brown adipose tissue without the hyperglycemic consequences. This three-pronged mechanism is designed to suppress appetite and increase calorie burning rather than relying on appetite suppression alone.

Eli Lilly is developing retatrutide, and it should not be confused with tirzepatide (Mounjaro/Zepbound), which is a dual GLP-1/GIP agonist. Retatrutide adds the glucagon component on top of that dual action.

The Weight Loss Data

Semaglutide (Approved Data)

The STEP 1 trial is the gold standard reference:

• Average weight loss: 14.9% of body weight
• Participants losing ≥20%: approximately 32%
• Duration: 68 weeks at 2.4 mg/week

The SURMOUNT-5 head-to-head trial (tirzepatide vs semaglutide) reinforced that dual agonism outperforms single GLP-1 agonism, setting a benchmark retatrutide aims to surpass.

Retatrutide (Phase II Data)

The Phase II trial published in The New England Journal of Medicine in 2023 produced striking results:

• Average weight loss at 24 weeks: up to 17.5% at the highest dose (12 mg/week)
• Projected loss at 48 weeks: modeling suggested approximately 24% in high-dose groups
• Participants losing ≥20% at 24 weeks: approximately 26% (extrapolated higher at full duration)

Phase III trials (TRIUMPH program) are ongoing. These numbers are not yet from a completed Phase III trial, which means they carry more uncertainty than the semaglutide data, but the trajectory is remarkable.

Side Effect Profile

Both molecules share a similar side effect pattern because GLP-1 agonism is central to both:

| Side Effect | Semaglutide | Retatrutide | |---|---|---| | Nausea | Very common (40–44%) | Very common (~40%) | | Vomiting | Common | Common | | Constipation | Common | Common | | Diarrhea | Common | Common | | Injection site reaction | Occasional | Occasional |

The glucagon component in retatrutide introduces a theoretically higher risk of nausea at initial doses because glucagon itself can trigger nausea. Phase II data showed most GI adverse events were mild to moderate and front-loaded during dose escalation, similar to semaglutide.

Neither agent has a clean long-term safety record in the way that medications approved for decades do. Semaglutide has post-marketing surveillance data now extending several years; retatrutide does not yet.

Muscle mass: Both GLP-1 agonists carry risk of lean mass loss alongside fat loss. Combining with resistance training and adequate protein (1.6–2.2 g/kg body weight) is recommended regardless of which agent is used. See our guide to peptides for muscle growth for complementary strategies.

Availability

This is where the practical gap is enormous:

• Semaglutide: FDA-approved as Ozempic (2.0 mg, type 2 diabetes) and Wegovy (2.4 mg, obesity). Compounded versions were widely available during the FDA shortage period, though the shortage was declared resolved in early 2025, tightening compounding access. See our separate comparison of compounded semaglutide vs brand Ozempic.
• Retatrutide: In Phase III trials as of early 2026. Not FDA-approved. Not legally available as a compounded medication in the US. Earliest projected approval: 2026–2027, pending Phase III data.

Anyone claiming to sell "retatrutide" for human use today is operating outside regulated channels. Research chemical suppliers exist, but these products carry no quality guarantee and no clinical safety oversight at therapeutic doses.

Which Should You Consider?

Semaglutide makes sense if you need an FDA-approved option today, you have insurance coverage, or your provider is familiar with dosing and monitoring protocols.

Retatrutide may be worth watching if you have not achieved adequate results with semaglutide or tirzepatide, or if Phase III data confirms the Phase II weight loss signal and it receives approval within your planning horizon.

For most people in 2026, the pragmatic answer is semaglutide (or tirzepatide) with a clinical team, not a research chemical pipeline. The GLP-1 class already produces life-changing weight loss outcomes when combined with behavioral changes.

Frequently Asked Questions

Q: Is retatrutide more effective than semaglutide? Early Phase II data suggests retatrutide may produce greater average weight loss, potentially in the 20–24% range at full doses versus 14–15% for semaglutide. However, Phase III confirmation is needed before drawing firm conclusions.

Q: When will retatrutide be FDA-approved? Eli Lilly's TRIUMPH Phase III trials were ongoing as of early 2026. An FDA submission could occur in late 2026 or 2027, with approval potentially following 6–12 months after submission if data supports it.

Q: Can you take semaglutide and then switch to retatrutide? Theoretically yes, with appropriate washout and dose titration under physician supervision. Many patients on GLP-1 therapy already switch between agents as coverage or efficacy dictates.

Q: Does retatrutide cause more side effects than semaglutide? Phase II data showed broadly similar GI side effect rates. The additional glucagon agonism may contribute slightly more nausea during titration, but this is manageable with slow dose escalation.

Q: What is the difference between retatrutide and tirzepatide? Tirzepatide is a dual GLP-1/GIP agonist (two receptors). Retatrutide adds glucagon receptor agonism on top, making it a triple agonist. See our full tirzepatide vs retatrutide comparison for detail.